Skip to content



Severe Acute Respiratory Syndrome CorOnaVirus 2 is a member of the betacoronavirus family and triggers a disease called Covid19. The original strain (pre-VOC) emerged in the wuhan district in the late 2019 and rapidly spread over the world. Several variants of concern emerged, including the delta and omicron variant.

It is an enveloped virus (70-110nm) with a positive single stranded RNA genome of around 30kb.


In January 2022, more than 367 millions of people has been infected by SARS-CoV-2, triggering more than 5 million death. This virus is present worlwide.

  • Primary infection can be completely asymptomatic in healthy individuals
  • Most of people will develop low to mild-severe infection, including fever, dryed cough, fatigue, nausea and diarhea
  • Can trigger severe to fatal disease in patient, including hospitalization in ICU and artificial ventilation.
  • All antiviral in development to date failed to reach market entry, vaccine available that greatly reduce severity of symptomes
  • We use this virus for the discovery of new antiviral molecules, testing of neutralizing antibodies and measurement of disinfection procedures
  • We have also a strong library of protocol for the contamination of different surface of interest, from plastic to living human skin explants
NeoVirtech lab BSL3
All SARS-CoV-2 experiments are done in an accreditated BSL3 laboratory.
Virus screening NeoVirtech
SARS-CoV-2 destroying human pulmonary cells 48h post-infection. Nuclei in blue, SARS NP in red and SARS RNA in green


We use SARS-CoV-2 and other respiratory viruses for a broad category of testing. Contact us to know more.